Evidence map›Paper›PMID 35914801›Full record

ArticleBMJ case reports2022

Choroidal effusion: a rare and unusual complication of daratumumab.

Aditi Singh, Talal Bazzi, Daniel Lebovic, Hakan Demirci

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Aditi SinghHematology Oncology, Ascension St John Hospital, Detroit, Michigan, USA aditisingh0215@gmail.com.ORCID http://orcid.org/0000-0002-9937-7048
Talal BazziInternal Medicine, Ascension St John Hospital, Detroit, Michigan, USA.
Daniel LebovicHematology Oncology, Ascension St John Hospital, Detroit, Michigan, USA.
Hakan DemirciW. K. Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USA.
St. John Hospital & Medical Center · USW.K. Kellogg Foundation · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Daratumumab-containing regimens are an effective treatment for advanced cases of multiple myeloma. Overall, daratumumab has a favourable safety profile, although rare side effects can occur. Rare side effects of daratumumab include choroidal effusion. Patients who begin to experience symptoms such as eye swelling, vision changes, eye discharge and blurry vision should undergo urgent ophthalmological evaluation and their daratumumab infusions held.

Indexed as

Choroidal EffusionsMultiple MyelomaAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsHumansTreatment OutcomeAntibodies, MonoclonaldaratumumabCancer - see OncologyDrugs and medicinesEyeHaematology (drugs and medicines)Immunological products and vaccines

Identifiers

PMID35914801
PMCPMC9344984
OpenAlexW4289334026

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.